Use of Serum Biomarkers to Aid Antidepressant Selection in Depressive Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: This study aimed to identify serum biomarkers prospectively associated with remission at 12 weeks in outpatients with depressive disorders receiving stepwise psychopharmacotherapy, according to the main antidepressant used during the treatment period. Methods: This study included 1,024 depressive outpatients initially treated using antidepressant monotherapy, followed by alternating pharmacological strategies during the acute phase (3−12 weeks; 3-week interval). Fourteen serum biomarkers, sociodemographics, and clinical characteristics were evaluated at baseline. Based on the use frequency and mechanism of action, four main antidepressant types were distinguished: escitalopram, other selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and mirtazapine. A Hamilton Depression Rating Scale score ≤ 7 was take to indicate remission. Results: Lower high-sensitivity C-reactive protein levels were correlated with remission at 12 weeks for all antidepressant types. Lower interleukin (IL)-6 levels and tumor necrosis factor-alpha levels were associated with remission using escitalopram and other SSRIs respectively. Lower IL-1β and leptin levels, predicted remission in association with SSRIs including escitalopram. For SNRIs, remission at 12 weeks was predicted by lower IL-4 and IL-10 levels. For mirtazapine, remission at 12 weeks was associated with lower leptin levels, and higher serotonin and folate levels. Conclusion: Baseline serum status, as estimated by nine serum markers, may help clinicians determine the most appropriate antidepressant to achieve remission in the acute phase of depression.
Abstract
Objective: This study aimed to identify serum biomarkers prospectively associated with remission at 12 weeks in outpatients with depressive disorders receiving stepwise psychopharmacotherapy, according to the main antidepressant used during the treatment period. Methods: This study included 1,024 depressive outpatients initially treated using antidepressant monotherapy, followed by alternating pharmacological strategies during the acute phase (3−12 weeks; 3-week interval). Fourteen serum biomarkers, sociodemographics, and clinical characteristics were evaluated at baseline. Based on the use frequency and mechanism of action, four main antidepressant types were distinguished: escitalopram, other selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and mirtazapine. A Hamilton Depression Rating Scale score ≤ 7 was take to indicate remission. Results: Lower high-sensitivity C-reactive protein levels were correlated with remission at 12 weeks for all antidepressant types. Lower interleukin (IL)-6 levels and tumor necrosis factor-alpha levels were associated with remission using escitalopram and other SSRIs respectively. Lower IL-1β and leptin levels, predicted remission in association with SSRIs including escitalopram. For SNRIs, remission at 12 weeks was predicted by lower IL-4 and IL-10 levels. For mirtazapine, remission at 12 weeks was associated with lower leptin levels, and higher serotonin and folate levels. Conclusion: Baseline serum status, as estimated by nine serum markers, may help clinicians determine the most appropriate antidepressant to achieve remission in the acute phase of depression.
참고문헌 (34)
- Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : A STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
- Pigott HE, "The STAR*D Trial : It is time to reexamine the clinical beliefs that guide the treatment of major depression", Can J Psychiatry, 60, pp.9~13 (2015)
- Liu JJ, "Peripheral cytokine levels and response to antidepressant treatment in depression : A systematic review and meta-analysis", Mol Psychiatry, 25, pp.339~350 (2020)
- Lee SH, "Plasminogen activator inhibitor-1 : Potential inflammatory marker in late-life depression", Clin Psychopharmacol Neurosci, 21, pp.147~161 (2023)
- Reddy PV, "Multiple complement pathway-related proteins might regulate immunopathogenesis of major depressive disorder", Clin Psychopharmacol Neurosci, 21, pp.313~319 (2023)
- Kim JM, "Possible link between serotonin and interleukin 18 on suicidality in patients with acute coronary syndrome", Clin Psychopharmacol Neurosci, 21, pp.386~390 (2023)
- Shi Y, "Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment : A systematic review and meta-analysis", Eur Neuropsychopharmacol, 41, pp.40~51 (2020)
- Kim JM, "Prospective associations of multimodal serum biomarkers with 12-week and 12-month remission in patients with depressive disorders receiving stepwise psychopharmacotherapy", Brain Behav Immun, 104, pp.65~73 (2022)
- Kang HJ, "The MAKE Biomarker discovery for Enhancing anTidepressant Treatment Effect and Response(MAKE BETTER)study : design and methodology", Psychiatry Investig, 15, pp.538~545 (2018)
- Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
- Perlman K, "A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder", J Affect Disord, 243, pp.503~515 (2019)
- Kim JM, "Predictors of 12-week remission in a nationwide cohort of people with depressive disorders : The CRESCEND study", Hum Psychopharmacol, 26, pp.41~50 (2011)
- Uher R, "An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline", Am J Psychiatry, 171, pp.1278~1286 (2014)
- Chang HH, "Treatment response and cognitive impairment in major depression : Association with C-reactive protein", Brain Behav Immun, 26, pp.90~95 (2012)
- Zhou J, "The association of C-reactive protein with responses to escitalopram antidepressant treatment in patients with major depressive disorder", J Affect Disord, 306, pp.32~38 (2022)
- Lindqvist D, "Oxidative stress, inflammation and treatment response in major depression", Psychoneuroendocrinology, 76, pp.197~205 (2017)
- Carboni L, "Biomarkers for response in major depression : comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies", Transl Psychiatry, 9, pp.182~ (2019)
- Eller T, "Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.445~450 (2008)
- Amitai M, "The relationship between plasma cytokine levels and response to selective serotonin reuptake inhibitor treatment in children and adolescents with depression and", or anxiety disorders, 2016, pp.26, 727~732
- Muthuramalingam A, "Effect of fluoxetine on inflammatory cytokines in drug-naive major depression : A short-term prospective study from South India", J Clin Psychopharmacol, 36, pp.726~728 (2016)
- Strawbridge R, "Inflammation and clinical response to treatment in depression : A meta-analysis", Eur Neuropsychopharmacol, 25, pp.1532~1543 (2015)
- Fornaro M, "Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds", J Affect Disord, 145, pp.300~307 (2013)
- Chen CY, "Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder", Psychoneuroendocrinology, 87, pp.108~118 (2018)
- Kloiber S, "Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels", Eur Neuropsychopharmacol, 23, pp.653~662 (2013)
- Machado-Vieira R, "The role of adipokines in the rapid antidepressant effects of ketamine", Mol Psychiatry, 22, pp.127~133 (2017)
- Choi W, "Interactive effects of serum leptin levels and physical comorbidity on the pharmacotherapeutic response of depressive disorders", Clin Psychopharmacol Neurosci, 20, pp.662~674 (2022)
- Gupta M, "TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder : Pharmacometabolomics-informed pharmacogenomics", Mol Psychiatry, 21, pp.1717~1725 (2016)
- Holck A, "Plasma serotonin levels are associated with antidepressant response to SSRIs", J Affect Disord, 250, pp.65~70 (2019)
- Figueras G, "Pretreatment platelet 5-HT concentration predicts the shortterm response to paroxetine in major depression. Grupo de Trastornos Afectivos", Biol Psychiatry, 46, pp.518~524 (1999)
- Alvarez JC, "Plasma serotonin level after 1 day of fluoxetine treatment : A biological predictor for antidepressant response?", Psychopharmacology(Berl), 143, pp.97~101 (1999)
- Alpert M, "Prediction of treatment response in geriatric depression from baseline folate level : interaction with an SSRI or a tricyclic antidepressant", J Clin Psychopharmacol, 23, pp.309~313 (2003)
- Hintikka J, "High vitamin B12 level and good treatment outcome may be associated in major depressive disorder", BMC Psychiatry, 3, pp.17~ (2003)
- Gupta R, "Effect of mirtazapine treatment on serum levels of brain-derived neurotrophic factor and tumor necrosis factor-α in patients of major depressive disorder with severe depression", Pharmacology, 97, pp.184~188 (2016)
- Atake K, "Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression", World J Biol Psychiatry, 23, pp.785~793 (2022)